{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:23:53Z","timestamp":1790342633321,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T00:00:00Z","timestamp":1575417600000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015362","name":"Amicus Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015362","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Fabry disease (FD) is a rare, X-linked, inherited lysosomal disease caused by absent or reduced \u03b1-galactosidase A activity. Due to the heterogeneity of disease presentation and progression, generic patient-reported outcome (PRO) tools do not provide accurate insight into patients\u2019 daily lives and impact of disease specific treatments. Also, the French National Health Authority, (HAS) actively encourages a patient-centric approach to improve the quality of care throughout the patient journey. In response to this initiative, we aimed to develop and validate a specific, self-reported, Patient Needs Questionnaire for people living with Fabry disease to appraise patient needs and expectations towards their treatment (PNQ Fabry). This endeavour was led with the help of French patient associations (APMF &amp; VML) and dedicated expert centres. PNQ Fabry was developed according to the FDA\/EMA methodologies and best practices for the development of PRO tools in rare diseases. Our approach comprised of three steps, as follows: concept elicitation and item generation, item reduction, and final validation of the questionnaire through a two-stage survey.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Intrinsic and extrinsic reliability was established, using a validated benchmark questionnaire. With the invaluable help of patient associations, we recruited a satisfactory population in this rare disease setting, to ensure robust participation to validate our PNQ (final number of questionnaires: 76). At the end of the process, a 26-item patient-reported questionnaire was obtained with excellent psychometric properties, exhibiting very satisfactory measurement outcomes for reliability and validity. The results of this initiative demonstrate that the PNQ Fabry is accurate, suitable and tailored to FD patients, as it addresses themes identified during patient interviews, that were further validated through statistical analyses of quantitative surveys. An ongoing phase IV study is using this tool.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We believe the PNQ Fabry will be a reliable and insightful tool in clinical practice, to improve patient management in FD.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-019-1254-7","type":"journal-article","created":{"date-parts":[[2019,12,4]],"date-time":"2019-12-04T19:03:28Z","timestamp":1575486208000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment needs and expectations for Fabry disease in France: development of a new Patient Needs Questionnaire"],"prefix":"10.1186","volume":"14","author":[{"given":"Esther","family":"No\u00ebl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Dussol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Lacombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najya","family":"Bedreddine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Fouilhoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Ronco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Genevaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumeya","family":"Bekri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Hag\u00e8ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Dupuis-Sim\u00e9on","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Derrien Ansquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique P.","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lidove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,4]]},"reference":[{"issue":"4","key":"1254_CR1","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1023\/A:1015511908710","volume":"11","author":"KF Gold","year":"2002","unstructured":"Gold KF, Pastores GM, Botteman MF, Yeh JM, Sweeney S, Aliski W, et al. Quality of life of patients with Fabry disease. Qual Life Res. 2002;11(4):317\u201327.","journal-title":"Qual Life Res"},{"issue":"4","key":"1254_CR2","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416\u201327.","journal-title":"Mol Genet Metab"},{"key":"1254_CR3","doi-asserted-by":"crossref","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5-30.","DOI":"10.1186\/1750-1172-5-30"},{"issue":"6","key":"1254_CR4","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1007\/s10545-009-1254-1","volume":"32","author":"TW Crosbie","year":"2009","unstructured":"Crosbie TW, Packman W, Packman S. Psychological aspects of patients with Fabry disease. J Inherit Metab Dis. 2009;32(6):745\u201353.","journal-title":"J Inherit Metab Dis"},{"key":"1254_CR5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","volume":"8","author":"CM Eng","year":"2006","unstructured":"Eng CM, Germain D, Banikazemi P, Warnock D M, Wanner C G, Hopkin RJ, LP BJ, Brodie SE SK, Pastores GM, Strotmann JM, Wilcox WR. Fabry disease: guidelines for the evaluation and management of multiorgan system involvement. Genet Med. 2006;8:539\u201348.","journal-title":"Genet Med"},{"key":"1254_CR6","unstructured":"Patient et Professionnels de Sant\u00e9 : d\u00e9cider ensemble. Concept, aides destin\u00e9es aux patients et impact de la d\u00e9cision m\u00e9dicale partag\u00e9e.: HAS (Haute Autorit\u00e9 de Sant\u00e9); 2013 [Available from: https:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2013-10\/synthese_avec_schema.pdf."},{"issue":"Suppl 1","key":"1254_CR7","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/j.1463-1326.2008.00882.x","volume":"10","author":"F Alvarez Guisasola","year":"2008","unstructured":"Alvarez Guisasola F, Tofe Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the real-life effectiveness and care patterns of diabetes management (RECAP-DM) study. Diabetes Obes Metab. 2008;10(Suppl 1):25\u201332.","journal-title":"Diabetes Obes Metab"},{"key":"1254_CR8","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.2147\/PPA.S102234","volume":"10","author":"J Greenberg","year":"2016","unstructured":"Greenberg J, Palmer JB, Chan WW, Correia CE, Whalley D, Shannon P, et al. Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder. Patient Prefer Adherence. 2016;10:2163\u20139.","journal-title":"Patient Prefer Adherence"},{"issue":"6","key":"1254_CR9","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1182\/blood-2004-01-0089","volume":"104","author":"DC Seldin","year":"2004","unstructured":"Seldin DC, Anderson JJ, Sanchorawala V, Malek K, Wright DG, Quillen K, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. Blood. 2004;104(6):1888\u201393.","journal-title":"Blood."},{"key":"1254_CR10","first-page":"971","volume":"9","author":"PP Khanna","year":"2015","unstructured":"Khanna PP, Shiozawa A, Walker V, Bancroft T, Essoi B, Akhras KS, et al. Health-related quality of life and treatment satisfaction in patients with gout: results from a cross-sectional study in a managed care setting. Patient Prefer Adherence. 2015;9:971\u201381.","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"1254_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12904-016-0172-x","volume":"15","author":"KM Fernstrom","year":"2016","unstructured":"Fernstrom KM, Shippee ND, Jones AL, Britt HR. Development and validation of a new patient experience tool in patients with serious illness. BMC Palliat Care. 2016;15(1):99.","journal-title":"BMC Palliat Care"},{"issue":"2","key":"1254_CR12","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2340\/00015555-2494","volume":"97","author":"S Stander","year":"2017","unstructured":"Stander S, Blome C, Anastasiadou Z, Zeidler C, Jung KA, Tsianakas A, et al. Dynamic pruritus score: evaluation of the validity and reliability of a new instrument to assess the course of pruritus. Acta Derm Venereol. 2017;97(2):230\u20134.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"1254_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1610-0387.2007.06540.x","volume":"6","author":"M Augustin","year":"2008","unstructured":"Augustin M, Reich C, Schaefer I, Zschocke I, Rustenbach SJ. Development and validation of a new instrument for the assessment of patient-defined benefit in the treatment of acne. J Dtsch Dermatol Ges. 2008;6(2):113\u201320.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"1254_CR14","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/mds.21745","volume":"24","author":"N Giladi","year":"2009","unstructured":"Giladi N, Tal J, Azulay T, Rascol O, Brooks DJ, Melamed E, et al. Validation of the freezing of gait questionnaire in patients with Parkinson's disease. Mov Disord. 2009;24(5):655\u201361.","journal-title":"Mov Disord"},{"key":"1254_CR15","doi-asserted-by":"crossref","unstructured":"Bowman SJ, Booth DA, Platts RG, Group UKSsI. Measurement of fatigue and discomfort in primary Sjogren's syndrome using a new questionnaire tool. Rheumatology (Oxford) 2004;43(6):758\u2013764.","DOI":"10.1093\/rheumatology\/keh170"},{"issue":"10","key":"1254_CR16","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1185\/030079906X132488","volume":"22","author":"R Freynhagen","year":"2006","unstructured":"Freynhagen R, Baron R, Gockel U, Tolle TR. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22(10):1911\u201320.","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"1254_CR17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13023-018-0761-2","volume":"13","author":"S Stein","year":"2018","unstructured":"Stein S, Bogard E, Boice N, Fernandez V, Field T, Gilstrap A, et al. Principles for interactions with biopharmaceutical companies: the development of guidelines for patient advocacy organizations in the field of rare diseases. Orphanet J Rare Dis. 2018;13(1):18.","journal-title":"Orphanet J Rare Dis"},{"key":"1254_CR18","doi-asserted-by":"crossref","unstructured":"Biegstraaten M, Arngrimsson R, Barbey F, Boks L, Cecchi F, Deegan PB, et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry working group consensus document. Orphanet J Rare Dis. 2015;10-36.","DOI":"10.1186\/s13023-015-0253-6"},{"key":"1254_CR19","unstructured":"(USDHHS) UDoHaHS. Guidance for industry. Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims 2009 [Available from: http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatory Information\/Guidances\/UCM193282.pdf.]"},{"key":"1254_CR20","unstructured":"European Medicines Agency. In: Oncology Working Party, Editor. Reflection paper on the use of patient reported outcome (PRO) measures in oncology studies: In; 2014."},{"issue":"7","key":"1254_CR21","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jval.2017.05.015","volume":"20","author":"K Benjamin","year":"2017","unstructured":"Benjamin K, Vernon MK, Patrick DL, Perfetto E, Nestler-Parr S, Burke L. Patient-reported outcome and observer-reported outcome assessment in rare disease clinical trials: an ISPOR COA emerging good practices task force report. Value Health. 2017;20(7):838\u201355.","journal-title":"Value Health"},{"issue":"3","key":"1254_CR22","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1159\/000195174","volume":"218","author":"M Augustin","year":"2009","unstructured":"Augustin M, Schafer I, Rabini S, Lee-Seifert C, Radtke M, Rustenbach SJ. Assessing the value of supportive skin care: development and validation of an instrument for evaluating patient-relevant benefit. Dermatology. 2009;218(3):255\u20139.","journal-title":"Dermatology"},{"issue":"3","key":"1254_CR23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/bjd.12664","volume":"170","author":"M Augustin","year":"2014","unstructured":"Augustin M, Blome C, Costanzo A, Dauden E, Ferrandiz C, Girolomoni G, et al. Nail assessment in psoriasis and psoriatic arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes. Br J Dermatol. 2014;170(3):591\u20138.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1254_CR24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.ejvs.2013.10.009","volume":"47","author":"C Blome","year":"2014","unstructured":"Blome C, Augustin M, Heyer K, Knofel J, Cornelsen H, Purwins S, et al. Evaluation of patient-relevant outcomes of lymphedema and lipedema treatment: development and validation of a new benefit tool. Eur J Vasc Endovasc Surg. 2014;47(1):100\u20137.","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"4","key":"1254_CR25","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/gim.2016.122","volume":"19","author":"ER Benjamin","year":"2017","unstructured":"Benjamin ER, Della Valle MC, Wu X, Katz E, Pruthi F, Bond S, et al. The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat. Genet Med. 2017;19(4):430\u20138.","journal-title":"Genet Med"},{"issue":"1","key":"1254_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","volume":"345","author":"CM Eng","year":"2001","unstructured":"Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry's disease. N Engl J Med. 2001;345(1):9\u201316.","journal-title":"N Engl J Med"},{"issue":"21","key":"1254_CR27","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001;285(21):2743\u20139.","journal-title":"JAMA"},{"issue":"6","key":"1254_CR28","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, et al. Treatment of Fabry's disease with the pharmacologic chaperone Migalastat. N Engl J Med. 2016;375(6):545\u201355.","journal-title":"N Engl J Med"},{"issue":"2","key":"1254_CR29","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1023\/A:1015009210639","volume":"11","author":"AH Miners","year":"2002","unstructured":"Miners AH, Holmes A, Sherr L, Jenkinson C, MacDermot KD. Assessment of health-related quality-of-life in males with Anderson Fabry disease before therapeutic intervention. Qual Life Res. 2002;11(2):127\u201333.","journal-title":"Qual Life Res"},{"key":"1254_CR30","unstructured":"FDA. Guidance for Industry: Patient-Reported Outcomes Measures: Use in Medical Product Development to Support Labeling Claims 2009."},{"issue":"3","key":"1254_CR31","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1017\/S0033291798006667","volume":"28","author":"Group TW","year":"1998","unstructured":"Group TW. Development of the World Health Organization WHOQOL-BREF quality of life assessment. Psychol Med. 1998;28(3):551\u20138.","journal-title":"Psychol Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1254-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-019-1254-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-019-1254-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T01:52:59Z","timestamp":1606960379000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-019-1254-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1254"],"URL":"https:\/\/doi.org\/10.1186\/s13023-019-1254-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"12 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This project was conducted in compliance with the French law regulating Research Involving Human Subjects (Law n\u00b0 2012\u2013300 March 3, 2012). The research design is excluded from French Ethics Committee approval according to article 2 decree n\u00b0 2017\u2013884 May 9, 2017.All participants received clear and detailed information about their involvement in developing this questionnaire, and their rights as a participant. All participants were informed before providing their informed consent and participating in any phase of the process.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"As part of the information letter, all participants were made aware that the results of this research may be published in a peer-reviewed medical journal (no individual data, only in an aggregate form). They all consented to have their data used in an aggregate form for publication purpose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare the following financial and non-financial competing interests: <b>E.N<\/b>: received honoraria from Amicus Therapeutics, Travel Expenses from Amicus Therapeutics, Sanofi and Shire. <b>B.D<\/b>: Advisory Board; Amicus Therapeutics. Travel Expenses; Sanofi. <b>N.B<\/b>: No conflicting interests to report. <b>A.F<\/b>: received honoraria for Advisory Board; Roles for Self; Amicus Therapeutics. Contracted Research; Roles for Self; Biomarin, Sanofi-Genzyme. Honoraria; Roles for Self; Amicus Therapeutics, Biomarin, Sanofi-Genzyme. Travel Expenses; Roles for Self; Amicus Therapeutics, Biomarin, Sanofi-Genzyme. <b>P.R:<\/b> Advisory Board; Roles for Self; Amicus Therapeutics. Consulting Fees; Roles for Self; Amicus Therapeutics, Idorsia. Contracted Research; Roles for Self; Alexion. Salaried Employee; Roles for Self; Sorbonne University, European Research Council. Honoraria; Roles for Self; Idorsia, Amgen. Travel Expenses; Roles for Self; Genzyme, International Society for Neurochemistry. <b>D.G<\/b>: No conflicting interests to report. <b>D.L<\/b>: Sanofi-Genzyme: contract\/honorarium. Amicus Therapeutics, Sanofi-Genzyme: advisory board participation congress. <b>S. B<\/b> received: Consulting Fees; Roles for Self; Amicus Therapeutics, Ultragenyx. Contracted Research; Roles for Self; Shire, Sanofi-Genzyme, Ultragenyx, Alexion. Travel Expenses; Roles for Self; Amicus Therapeutics, Sanofi-Genzyme, Shire. <b>A.H<\/b>: Advisory Board; Roles for Self; Novartis. Consulting Fees; Roles for Self; Pfizer, Amicus Therapeutics, Sanofi-Genzyme, Alnylam. Contracted Research; Roles for Self; Amicus Therapeutics, Genzyme, Gilead. Honoraria; Roles for Self; Pfizer, Amicus Therapeutics, Sanofi-Genzyme, Novartis. <b>F.D-S<\/b>: employee Amicus Therapeutics. <b>V.D-A<\/b>: subcontracted by Amicus Therapeutics. <b>D.P.G<\/b>: received travel grants and speaker honoraria from Amicus Therapeutics, Sanofi and Takeda. <b>O.L<\/b>: Travel grants and speaker honoraria from: Amicus Therapeutics, Genzyme\/Sanofi, and Shire.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"284"}}